The estimated Net Worth of Daniel M Bollag is at least $355 Thousand dollars as of 6 December 2018. Daniel Bollag owns over 17,400 units of Ocular Therapeutix Inc stock worth over $355,324 and over the last 7 years Daniel sold OCUL stock worth over $0.
Daniel has made over 2 trades of the Ocular Therapeutix Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Daniel bought 17,400 units of OCUL stock worth $100,224 on 6 December 2018.
The largest trade Daniel's ever made was buying 24,700 units of Ocular Therapeutix Inc stock on 7 December 2017 worth over $97,071. On average, Daniel trades about 8,420 units every 73 days since 2017. As of 6 December 2018 Daniel still owns at least 42,100 units of Ocular Therapeutix Inc stock.
You can see the complete history of Daniel Bollag stock trades at the bottom of the page.
Daniel's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer, and Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: